Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?

PAUL MATHEW, GREGORY J. AHMANN, THOMAS E. WITZIG, PATRICK C. ROCHE, ROBERT A. KYLE, PHILIP R. GREIPP

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Summary. Prior studies have suggested that loss of plasma cell CD 5 6 expression in multiple myeloma defines a unique patient subset and that CD56 expression reliably discriminates between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). We conducted a study of 68 untreated patients with MM from a single institution to define the clinicopathological correlates of CD56 expression. We find CD56 expression in 55% of MM. Lack of CD56 expression does not define a unique clinicopathological or prognostic entity in MM. Strong CD 5 6 expression can also be found in MGUS and does not help to distinguish from MM.

Original languageEnglish (US)
Pages (from-to)459-461
Number of pages3
JournalBritish journal of haematology
Volume90
Issue number2
DOIs
StatePublished - Jun 1995

Keywords

  • CD56
  • expression
  • multiple myeloma

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?'. Together they form a unique fingerprint.

  • Cite this